Literature DB >> 10403542

Genetic properties for the suppression of development of putative preneoplastic glutathione S-transferase placental form-positive foci in the liver of carcinogen-resistant DRH strain rats.

A Denda1, W Kitayama, Y Konishi, Y Yan, Y Fukamachi, M Miura, S Gotoh, K Ikemura, T Abe, T Higashi, K Higashi.   

Abstract

The post-initiation stage of hepatocarcinogenesis was investigated in carcinogen-resistant inbred DRH rats and the parental strain, carcinogen-sensitive Donryu rats. Male rats at 5 weeks of age from both strains were treated with N-nitrosodiethylamine (200 mg/kg i.p.) followed by feeding with a diet containing 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB) from 2 weeks later and were then subjected to partial hepatectomy at 1 week later. At 8 weeks after the start of treatment, the mean area occupied by glutathione S-transferase placental form (GST-P)-positive lesions was about 30% in Donryu rats but less than 4% in DRH rats despite the presence of comparable numbers of foci in the livers of both strains. These observations suggested that clonal expansion of GST-P-positive foci in DRH rat liver was significantly suppressed under these conditions. Furthermore, this genetic property was dominantly inherited in the F1 rats by crosses of DRH and carcinogen-sensitive inbred F344 rats; that is, the induction of GST-P mRNA in the livers of F344 x DRH F1 rats was dominantly suppressed after administration of 3'-Me-DAB for 8 weeks as compared with parental F344 rats under the same conditions. We compared the intrinsic properties related to growth potential of liver cells between adult DRH and Donryu rats. DRH rat liver showed retarded and/or reduced DNA synthesis after partial hepatectomy or a single i.v. injection of lead nitrate and lower activity of telomerase induced by 3'-Me-DAB administration for 1 week, as compared with the Donryu rat liver. The intrinsic properties observed in this study may be related, at least in part, to the low incidence of liver tumors induced by hepatocarcinogens in DRH rats.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10403542     DOI: 10.1016/s0304-3835(99)00051-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats.

Authors:  Yan-Tong Guo; Xi-Sheng Leng; Tao Li; Jing-Ming Zhao; Xi-Hou Lin
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

2.  Interaction of major genes predisposing to hepatocellular carcinoma with genes encoding signal transduction pathways influences tumor phenotype and prognosis.

Authors:  Francesco Feo; Maddalena Frau; Rosa-Maria Pascale
Journal:  World J Gastroenterol       Date:  2008-11-21       Impact factor: 5.742

3.  Hepatic gap junctions in the hepatocarcinogen-resistant DRH rat.

Authors:  Takahiro Gotow; Motoko Shiozaki; Taneaki Higashi; Kentaro Yoshimura; Masahiro Shibata; Eiki Kominami; Yasuo Uchiyama
Journal:  Histochem Cell Biol       Date:  2008-07-17       Impact factor: 4.304

4.  Unique Properties of Hepatocarcinogenesis-Resistant DRH Rat Hepatocytes Linked or Not Linked to the Drh1 Locus on Rat Chromosome 1.

Authors:  Norikazu Hashimoto; Masahiro Yamamoto; Masaaki Miyakoshi; Hiroki Tanaka; Katsuhiro Ogawa
Journal:  Int J Hepatol       Date:  2011-07-25

Review 5.  Experimental Models to Define the Genetic Predisposition to Liver Cancer.

Authors:  Rosa M Pascale; Maria M Simile; Graziella Peitta; Maria A Seddaiu; Francesco Feo; Diego F Calvisi
Journal:  Cancers (Basel)       Date:  2019-09-27       Impact factor: 6.639

6.  Aristolochic acid I promoted clonal expansion but did not induce hepatocellular carcinoma in adult rats.

Authors:  Yong-Zhen Liu; Heng-Lei Lu; Xin-Ming Qi; Guo-Zhen Xing; Xin Wang; Pan Yu; Lu Liu; Fang-Fang Yang; Xiao-Lan Ding; Ze-An Zhang; Zhong-Ping Deng; Li-Kun Gong; Jin Ren
Journal:  Acta Pharmacol Sin       Date:  2021-03-08       Impact factor: 7.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.